Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2074818 | 0.85 | USP2 (0.44) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL213460 | 0.82 | EPHX2 (0.44) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL16993333 | 0.82 | USP2 (0.42) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| Hydrochloric Acid SCHEMBL20423977 | 0.81 | EPHX2 (0.43) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL23487060 | 0.81 | USP2 (0.46) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL25326751 | 0.80 | USP2 (0.40) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL4998535 | 0.80 | USP2 (0.51) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL309615 | 0.78 | USP2 (0.46) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL8242595 | 0.78 | USP2 (0.61) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL18294 | 0.77 | USP2 (0.69) | USP2SMN1; SMN2GPR119HPGDEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1057815-B1 | CYCLIC AMIDE COMPOUNDS | KOWA CO (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-6645957-B2 | Useful in preventing and treating allergic immunological diseases; treating asthma, atopic dermatitis, allergic rhinitis, inflammatory large bowel disease, contact dermatitis | KOWA CO., LTD. (JP) | 2003-11-11 | — | — | US | disclosed |
| US-20030096828-A1 | Cyclic amide compound | KOWA CO., LTD. (JP) | 2003-05-22 | — | — | US | disclosed |
| US-6448242-B1 | COMPOUND HAVING A STRONG INHIBITORY EFFECT ON THE PRODUCTION OF AN IGE ANTIBODY; ANTIALLERGENS | KOWA CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| EP-1057815-A1 | CYCLIC AMIDE COMPOUNDS | Kowa Co., Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096828-A1 | Cyclic amide compound | CMA1, HRH2, HRH4 | USP2 3827/4885SMN1; SMN2 4567/4885CHRM2 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.